Results 81 to 90 of about 28,236 (118)

Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis. [PDF]

Clin Mol Hepatol
Choi J, Fulop D, Nguyen VH, Przybyszewski E, Song J, Carroll A, Michta M, Almazan E, Simon TG, Chung RT.   +9 more
europepmc   +1 more source

Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]

BMC Pharmacol Toxicol
Hayakawa T, Akimoto H, Nagashima T, Minagawa K, Takahashi Y, Asai S.   +5 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: A global retrospective cohort study. [PDF]

Clin Rheumatol
Wang Q, Anthony DD.
europepmc   +1 more source

New Insights into the Pleiotropic Actions of Dipeptidyl Peptidase-4 Inhibitors Beyond Glycaemic Control. [PDF]

touchREV Endocrinol
Mangoura SA, Ahmed MA, Zaka AZ.
europepmc   +1 more source

Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes. [PDF]

J Am Heart Assoc
Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M.   +9 more
europepmc   +1 more source

Impact of dipeptidyl peptidase-4 inhibitors on incidence of colorectal cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. [PDF]

Ther Adv Drug Saf
Fu R, Chen J, Fang Y, Wu Q, Zhang X, Wang Z.   +5 more
europepmc   +1 more source

Restoring Brain Pathways Involved in Diabetes-Associated Neurocognitive Disorders: The Potential of Dipeptidyl Peptidase 4 Inhibitors as a Therapeutic Strategy. [PDF]

Curr Neuropharmacol
Piatkowska-Chmiel I, Gawronska-Grzywacz M, PawLowski K, Dudka J, Slaska B, Tkaczyk-Wlizlo A, Kowal K, Herbet M.   +7 more
europepmc   +1 more source

Dipeptidyl peptidase 4 inhibitors reduce the risk of adverse outcomes after acute kidney injury in diabetic patients. [PDF]

Clin Kidney J
Liao HW, Cheng CY, Chen HY, Chen JY, Pan HC, Huang TM, Wu VC.   +6 more
europepmc   +1 more source

Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases. [PDF]

Pharmacol Rev
Steven S, Kuntic M, Münzel T, Daiber A.
europepmc   +1 more source

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study. [PDF]

Front Pharmacol
Li YC, Kuan YH, Yang Y, Gau SY, Su KY, Tsai TH, Huang KH, Lee CY.   +7 more
europepmc   +1 more source